For the CY 2025 performance period/2027 MIPS payment year, using our currently approved per response time estimates for the clinicians and subgroups submitting data for the MVP quality performance category, we estimated a burden of 16,059 hours [5.3 hr 3,030 (3,020 +10) responses] at a cost of $1,954,138 (3,030 responses $644.93/response) for the eCQM collection type, 11,343 hours [5.97 hr 1,900 (1,890 +10 responses)] at a cost of $1,360,989 (1,900 responses $716.31/response) for the MIPS CQM and QCDR collection type, and 12,791 hours (9.44 hr 1,355 responses) at a cost of $1,492,180 (1,355 responses $1,101.24/response) for the Medicare Part B claims collection type
Frank deficiency (below 145 pmol/L), post-RYGB or post-BPD-DS: intramuscular injection, loading regimen followed by monthly maintenance
Contract Year 2024 Policy and Technical Changes to the ( Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly
AOD-9604 is particularly remarkable for its ability to decrease fat stores in the abdominal region
It is not approved for human or veterinary use , and no dosage, administration, or clinical guidance is provided or implied